This post was originally published on this site
https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEG5M15S_L.jpg
The drugmaker said it has also secured the right to acquire remainder of Pionyr for a $315 million option exercise fee.
Gilead to buy 49.9% stake in cancer drug developer Pionyr for $275 million
4 years ago
No Comments
Related Posts
Elon Musk Spent $2.64 Billion on Twitter Stock
April 6, 2022
Ex-Tesla president sold stocks worth $247 million since June 10 – SEC filing
June 19, 2021
This product kills COVID for 7 days—and just got EPA approval for some American Airlines planes
August 24, 2020
Teledentistry is filling a cavity left by the pandemic, but some caution it can’t replace in-person visits
October 21, 2020
StockBeat: The Dam Breaks in Europe
October 15, 2020
General Motors and GlobalFoundries announce long-term direct supply agreement
February 9, 2023
About The Author
